Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged 18 to 60 years, from both sex, and suffering from multiple sclerosis either primary progressive or secondary progressive without relapse within 2 years before inclusion.~2. Patients with EDSS score in the range of 2 to 6.5, inclusive~3. EDSS progression ≥ 1 point within 2 years before inclusion~Exclusion Criteria:~1. Disease other than MS responsible for clinical signs and/or MRI lesions~2. Secondary progressive MS with relapse in the 2 years before inclusion~3. Treatment with interferon or glatiramer acetate within four weeks prior to treatment allocation~4. Treatment with oral or systemic corticosteroids or ACTH within four weeks prior to treatment allocation.~5. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- masitinib 3 mg/kg/day (Type: EXPERIMENTAL): None
- masitinib 6 mg/kg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).